Dynamic risk stratification using early CAR ‐T expansion in R/R LBCL treated with axicabtagene ciloleucel
British Journal of Haematology · 07.09.2026
DOI: 10.1111/bjh.70825 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 07.09.2026. Verfasst von Brydon Panozzo und 17 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The clinical utility of routine monitoring of chimeric antigen receptor (CAR) T‐cell expansion post‐infusion remains controversial. We conducted a retrospective analysis of a prospectively collected cohort of 176 patients with relapsed/refractory large B‐cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi‐cel). CAR T‐cell expansion was measured by flow cytometry at days 7, 14 and 28 following infusion with real‐time reporting to the clinical service in 111 patients. We examined the association between CAR T‐cell expansion, efficacy (progression‐free survival [PFS]), toxicity (cytokine release syndrome [CRS] and immune effector cell‐associated neurotoxicity syndrome [ICANS]) and toxicity management, accounting for baseline risk factors. A multivariable model combining day 7 expansion with pre‐lymphodepletion lactate dehydrogenase (LDH) and bridging response demonstrated that robust day 7 expansion (≥48 cells/μL) was independently associated with improved PFS (hazard ratio [HR], 0.43; 95% confidence interval [CI] 0.22–0.83; p = 0.01). Higher day 7 expansion was associated with increased CRS severity and ICANS incidence. Higher corticosteroid exposure reflected this toxicity burden but was not associated with inferior PFS. Thus, incorporating quantitative CAR‐T enumeration into clinical practice may dynamically refine risk stratification post‐infusion and guide individualised management, such as the frequency of monitoring for progressive disease in the era of effective subsequent therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia.
- Malignant Haematology, Transplantation and Cellular Therapy Service, Alfred Hospital, Melbourne, Victoria, Australia.
- Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
- Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia.
- Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
ORCID-Profile: Brydon Panozzo, Adrian G Minson, Kylie Baldwin, Hamish W Scott, Jane Oliaro, Aaron J N Wong, Samantha van der Linde, Nicole L O'Leary, John F Seymour, Mary Ann Anderson, Constantine S Tam, Simon J Harrison, Michael J Dickinson, Mark R Dowling
Zitieren
APA
Panozzo, B., Robinson, S., Minson, A. G., Li, J., Baldwin, K., Scott, H. W., Oliaro, J., Wong, A. J. N., van der Linde, S., O'Leary, N. L., Thompson, P. A., Seymour, J. F., Anderson, M. A., Tam, C. S., Harrison, S. J., Dickinson, M. J., Westerman, D. A., & Dowling, M. R. (2026). Dynamic risk stratification using early CAR ‐T expansion in R/R LBCL treated with axicabtagene ciloleucel. British Journal of Haematology. https://doi.org/10.1111/bjh.70825
Vancouver
Panozzo B, Robinson S, Minson AG, Li J, Baldwin K, Scott HW, et al. Dynamic risk stratification using early CAR ‐T expansion in R/R LBCL treated with axicabtagene ciloleucel. British Journal of Haematology. 2026. doi:10.1111/bjh.70825
BibTeX
@article{Panozzo2026,
author = {Panozzo, Brydon and Robinson, Samuel and Minson, Adrian G and Li, Jian and Baldwin, Kylie and Scott, Hamish W and Oliaro, Jane and Wong, Aaron J N and van der Linde, Samantha and O'Leary, Nicole L and Thompson, Philip A and Seymour, John F and Anderson, Mary Ann and Tam, Constantine S and Harrison, Simon J and Dickinson, Michael J and Westerman, David A and Dowling, Mark R},
title = {Dynamic risk stratification using early CAR ‐T expansion in R/R LBCL treated with axicabtagene ciloleucel},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70825}
}
EUVIMED